HC Wainwright Reaffirms Buy Rating for Alpha Tau Medical (NASDAQ:DRTS)

Alpha Tau Medical (NASDAQ:DRTS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $16.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 22.10% from the company’s current price.

DRTS has been the topic of several other reports. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Barclays increased their target price on shares of Alpha Tau Medical from $17.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, September 3rd. Benchmark reiterated a “buy” rating on shares of Alpha Tau Medical in a research note on Thursday, July 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Alpha Tau Medical has a consensus rating of “Hold” and a consensus target price of $15.40.

Alpha Tau Medical Stock Performance

DRTS traded up $0.48 on Tuesday, hitting $13.10. The company’s stock had a trading volume of 314,619 shares, compared to its average volume of 582,206. The company’s 50 day simple moving average is $14.47 and its 200-day simple moving average is $11.73. The firm has a market cap of $1.18 billion, a P/E ratio of -12.62 and a beta of 1.22. Alpha Tau Medical has a 12 month low of $3.43 and a 12 month high of $15.79. The company has a quick ratio of 7.79, a current ratio of 11.09 and a debt-to-equity ratio of 0.15.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.36). Analysts forecast that Alpha Tau Medical will post -1.05 EPS for the current year.

Insider Transactions at Alpha Tau Medical

In related news, CFO Raphi Levy sold 17,730 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.00, for a total value of $248,220.00. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at approximately $1,262,520. The trade was a 16.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 39.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Everhart Financial Group Inc. bought a new stake in Alpha Tau Medical in the 2nd quarter worth $126,000. Principal Financial Group Inc. bought a new stake in Alpha Tau Medical in the 1st quarter worth $132,000. Finally, Renaissance Technologies LLC bought a new stake in Alpha Tau Medical in the 1st quarter worth $286,000. Institutional investors own 2.65% of the company’s stock.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is an Israel-based medical technology company focused on developing localized radiation treatments for solid tumors. Its lead technology, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), is designed to deliver high-energy alpha radiation directly within a tumor while limiting exposure to surrounding healthy tissue.

Alpha DaRT uses implanted radium-224 sources that generate short-lived alpha-emitting atoms. These atoms diffuse through the treated tumor and can damage cancer cells over a localized area.